Chairman of the Board since 2017. Pharmacy degree.
Experience: Ola has nearly 50 years of experience from the pharmaceutical industry, including Astra Zeneca, ACO Pharmaceuticals, and as a consultant regarding drug development and experience as an investor in Life Science. Ola is a board member (and former chairman) of Asarina Pharma AB, which was recently listed on Nasdaq First North.
Ongoing assignment: Chairman of Pens. Pharmaceutical Association. Board member of Asarina Pharma AB (publ) and in Ola Flink Consulting AB. Member of the Nomination Committee for Brf Tullstugan 3.
Previous assignments in the past five years: Board member of Umecrine Cognition AB and Marbileads AS Norway.
Owns more than five percent of the shares in: Ola Flink Consulting AB.
Holding in the Company: 455,334 shares, 16,667 warrants (TO1), 50,000 call options.
Ola Flink is independent in relation to the Company and the Company’s largest owner
Board member since 2014. Degree in Chemistry and holds a Ph.D in Natural Sciences from the Swiss Federal Institute in Zürich (ETHZ).
Experience: Gabriel is an employee of Cerbios-Pharma SA (Switzerland) who specializes in the development and manufacture of chemical and organic pharmaceutical ingredients, so-called APIs. Gabriel has over 20 years of international experience from the pharmaceutical industry and has, among other things, worked with business development and has been Head of Commercial Division for Chemical contract manufacturing operations at Helsinn Pharmaceutical Group.
Ongoing assignment: Employee of Cerbios-Pharma SA and GMT Fine Chemicals SA. Board member of Chemelectiva SA.
Previous assignments in the last five years: –
Owns more than five percent of the shares in: –
Holdings in the Company: 65,300 shares, 15,800 warrants. Gabriel Haering is employed by Cerbios-Pharma SA, which owns 488,750 shares in Lipidor.
Board member since 2019.
Experience: Gunilla is the CEO of Uppsala University’s holding company since 2018. Prior to that she has had several leading positions in large, medium-sized and small life science companies. These include Pharmacia, Q-med and Pharmanest.
Ongoing assignment: CEO of Uppsala University’s holding company, Board member of Exscale Biospecimen Solutions AB, The Institute for Personnel and Corporate Development AB, Chordate Medical AB (publ.) And AddBio AB
Previous assignments in the last five years: [possibly supplemented]
Owns more than five percent of the shares in: [possibly supplemented]
Holdings in the Company: 0 shares, 0 warrants.
Gunilla Lundmark is independent in relation to the Company and the Company’s largest owner
Board member since 2018. Trained civil engineer in automation technology and a master’s degree in business development.
Experience: Fredrik is CEO of Inhalation Sciences AB and was previously CEO of PharmaSurgics in Sweden AB and Promore Pharma AB (formerly Lipopeptide). Fredrik has more than 10 years of experience in managing and listing Swedish life science companies as President and Chairman of the Board.
Ongoing assignment: Chairman of Inhalation Sciences Sweden AB, Ziccum AB and Monivent AB. Member of the Board of Axelero AB.
Previous assignments in the past five years: Chairman of Hemcheck Sweden AB.
Owns more than five percent of the shares in: Axelero AB.
Holding in the Company: 0 shares, 50,000 call options.
Fredrik Sjövall is independent in relation to the Company and the Company’s largest owner
Board member since 2018. Degree from the Stockholm School of Economics.
Experience: Per is CEO of Råsunda Förvaltning AB and has over 15 years of experience in financing and developing innovative growth companies.
Ongoing assignment: CEO and member of the board of Råsunda management company. Board member of ICTA AB (publ).
Previous assignments in the past five years: Board member of OraSolv AB and Inhalation Sciences Sweden AB.
Owns more than five percent of the shares in: Lipidor AB and Råsunda Förvaltning AB. Has previously been active, and in the past five years owned more than five percent of the shares, in Inhalation Sciences AB.
Holdings in the Company: 0 shares, 0 warrants. Per Nilsson is a shareholder, board member and CEO of Råsunda Förvaltnings AB, which owns 3,942,750 shares in Lipidor.